6461 Stock Overview
Intech Biopharm Corporation engages in developing and manufacturing generic drugs to treat respiratory diseases in Taiwan and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Intech Biopharm Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$26.95 |
| 52 Week High | NT$38.00 |
| 52 Week Low | NT$24.00 |
| Beta | 0.37 |
| 1 Month Change | -3.41% |
| 3 Month Change | -5.77% |
| 1 Year Change | -24.08% |
| 3 Year Change | 16.92% |
| 5 Year Change | 15.67% |
| Change since IPO | -69.72% |
Recent News & Updates
Shareholder Returns
| 6461 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | -3.4% | -1.5% | -0.6% |
| 1Y | -24.1% | 8.8% | 29.2% |
Return vs Industry: 6461 underperformed the TW Pharmaceuticals industry which returned 8.8% over the past year.
Return vs Market: 6461 underperformed the TW Market which returned 29.2% over the past year.
Price Volatility
| 6461 volatility | |
|---|---|
| 6461 Average Weekly Movement | 3.7% |
| Pharmaceuticals Industry Average Movement | 3.8% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in TW Market | 8.7% |
| 10% least volatile stocks in TW Market | 2.2% |
Stable Share Price: 6461 has not had significant price volatility in the past 3 months.
Volatility Over Time: 6461's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 82 | William Wu | www.intechbiopharm.com |
Intech Biopharm Corporation engages in developing and manufacturing generic drugs to treat respiratory diseases in Taiwan and internationally. It owns iLEF (inhaled low ethanol formulation), a metered dose inhaler platform for treating asthma and COPD; and dry powder inhaler, a product comprises of blisters and capsules. The company offers its products under the SYN006, SYN010, SYN007, Synflutide, Duasma, Synvent, and SYN011 names.
Intech Biopharm Corporation Fundamentals Summary
| 6461 fundamental statistics | |
|---|---|
| Market cap | NT$3.70b |
| Earnings (TTM) | -NT$337.99m |
| Revenue (TTM) | NT$25.85m |
143.3x
P/S Ratio-11.0x
P/E RatioIs 6461 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6461 income statement (TTM) | |
|---|---|
| Revenue | NT$25.85m |
| Cost of Revenue | NT$189.84m |
| Gross Profit | -NT$163.99m |
| Other Expenses | NT$173.99m |
| Earnings | -NT$337.99m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.46 |
| Gross Margin | -634.48% |
| Net Profit Margin | -1,307.65% |
| Debt/Equity Ratio | 122.9% |
How did 6461 perform over the long term?
See historical performance and comparison